IL150961A0 - Human immunodeficiency virus vaccine - Google Patents

Human immunodeficiency virus vaccine

Info

Publication number
IL150961A0
IL150961A0 IL15096101A IL15096101A IL150961A0 IL 150961 A0 IL150961 A0 IL 150961A0 IL 15096101 A IL15096101 A IL 15096101A IL 15096101 A IL15096101 A IL 15096101A IL 150961 A0 IL150961 A0 IL 150961A0
Authority
IL
Israel
Prior art keywords
immunodeficiency virus
human immunodeficiency
virus vaccine
vaccine
human
Prior art date
Application number
IL15096101A
Other languages
English (en)
Original Assignee
Univ Duke
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Beth Israel Hospital filed Critical Univ Duke
Publication of IL150961A0 publication Critical patent/IL150961A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15096101A 2000-02-04 2001-02-05 Human immunodeficiency virus vaccine IL150961A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49749700A 2000-02-04 2000-02-04
PCT/US2001/003540 WO2001056355A2 (fr) 2000-02-04 2001-02-05 Vaccin contre le virus de l'immunodeficience humaine

Publications (1)

Publication Number Publication Date
IL150961A0 true IL150961A0 (en) 2003-02-12

Family

ID=23977124

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15096101A IL150961A0 (en) 2000-02-04 2001-02-05 Human immunodeficiency virus vaccine

Country Status (11)

Country Link
US (4) US6982086B2 (fr)
EP (1) EP1307130A4 (fr)
JP (1) JP2004503205A (fr)
KR (2) KR20070057273A (fr)
CN (1) CN1635876A (fr)
AU (1) AU785143B2 (fr)
BR (1) BR0108210A (fr)
CA (1) CA2398816A1 (fr)
IL (1) IL150961A0 (fr)
MX (1) MXPA02007478A (fr)
WO (1) WO2001056355A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
EP1307130A4 (fr) 2000-02-04 2005-01-12 Beth Israel Hospital Vaccin contre le virus de l'immunodeficience humaine
EP1331942A4 (fr) 2000-09-22 2005-03-16 Univ Duke Immunogene contenant la proteine d'enveloppe du vih liee a un ligand
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
US7172761B2 (en) * 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
US7195768B2 (en) * 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
US7153509B2 (en) 2001-11-07 2006-12-26 Duke University Immunogenic peptides comprising a T-helper epitope and a B-cell neutralizing antibody epitope
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
AU2003297155B2 (en) * 2002-12-16 2010-03-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing IL-15 and methods of using the same
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US20060205070A1 (en) * 2004-01-13 2006-09-14 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services HIV TEV compositions and methods of use
US20050249428A1 (en) * 2004-05-07 2005-11-10 Ming-Jun Chen Method of weeding out repeating patterns from programs
EP1805134B1 (fr) 2004-10-25 2012-06-20 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines et procedes d'utilisation
US20080038284A1 (en) * 2004-11-08 2008-02-14 Haynes Barton F Human Immunodeficiency Virus Vaccine
WO2006110344A1 (fr) * 2005-04-07 2006-10-19 Wyeth Nouvelles methodes permettant d'induire une reponse immunitaire contre le virus de l'immunodeficience humaine
TW200726479A (en) * 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2007055952A2 (fr) * 2005-11-03 2007-05-18 Wyeth Procede de production de peptides th-ctl du vih stables
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
CN101969975B (zh) * 2008-01-31 2013-06-05 生控基因疫苗股份有限公司 作为疫苗的hiv嵌合融合蛋白
US20100075012A1 (en) * 2008-09-19 2010-03-25 Glanbia Nutritionals Ireland Limited Flax substitution methods and food products
FR2946620A1 (fr) 2009-06-16 2010-12-17 Eurocopter France Procede d'aide au pilotage,moyen d'aide au pilotage et dispositif d'aide au pilotage d'un giravion utilisant ledit moyen d'aide au pilotage pour mettre en oeuvre ledit procede d'aide au pilotage.
CN102060929A (zh) * 2010-06-07 2011-05-18 夏书奇 T细胞免疫平衡肽
US9327009B2 (en) * 2012-03-02 2016-05-03 Council Of Scientific And Industrial Research Peptide inhibitors as novel anti-HIV therapeutics
EP2745845A1 (fr) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux Procédé de prévention ou de traitement d'une infection par VIH
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
WO2020186064A1 (fr) * 2019-03-12 2020-09-17 The General Hospital Corporation Composition immunogène en réseau très dense

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930000189B1 (ko) * 1984-10-18 1993-01-11 앵스뛰띠 빠스뙤르 임파선증과 후천성 면역 결핍증 바이러스의 항원을 제조하는 방법 및 이 항원에 대한 항체의 생산 방법
CA1341482C (fr) 1984-10-31 2005-05-10 Paul A. Luciw Procede de preparation de fragments de retrovirus du groupe du sida
US5853978A (en) 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
US6290963B1 (en) 1986-08-22 2001-09-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-HIV compositions containing native and recombinant peptides
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5081226A (en) 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
US5976541A (en) 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US5030449A (en) 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
US5939074A (en) 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
AU592258B2 (en) 1986-12-30 1990-01-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
US5993819A (en) 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
US5019387A (en) 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5820865A (en) 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
US5516632A (en) 1988-02-08 1996-05-14 Duke University Synthetic peptides
US5882853A (en) 1989-09-01 1999-03-16 The United States Of America As Represented By The Department Of Health And Human Services Method of evaluating HTLV-I-specific T cell responses
CA2025634A1 (fr) 1989-09-19 1991-03-20 Thomas Fuerst Peptides comprenant des epitopes ctl de proteines de hiv et leur utilisation
SE468168B (sv) * 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
US5336758A (en) 1990-03-09 1994-08-09 The United States Of America As Represented By The Department Of Health And Human Services Peptides stimulating cytotoxic T cells immune to HIV RT
CA2114849C (fr) 1991-08-29 2007-04-24 Jay A. Berzofsky Antigenes peptidiques multideterminants qui stimulent la reponse des lymphocytes t auxiliaires contre le hiv chez une gamme de sujets humains
US5976551A (en) * 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
ATE193208T1 (de) 1992-02-10 2000-06-15 Univ Duke Verwendung synthetischer peptide zur induktion der toleranz gegen t- und b-zell epitope von autoantigenen
US5980899A (en) 1992-06-10 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells
US5997869A (en) 1993-03-15 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens
ATE247485T1 (de) 1993-04-16 2003-09-15 Tripep Ab Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
WO1994028871A1 (fr) * 1993-06-07 1994-12-22 Endocon, Inc. Immunite a mediation cellulaire stimulee par implant
EP0708659A4 (fr) 1993-06-07 2000-08-23 Genentech Inc Polypeptides d'enveloppe du vih
CA2164818C (fr) 1993-06-09 2003-09-23 Charles D.Y. Sia Peptides synthetiques en tandem, vaccins contre le vih-1
US5519114A (en) 1993-10-29 1996-05-21 University Of Florida Research Foundation, Inc. Retroviral superantigens, superantigen peptides, and methods of use
ATE221786T1 (de) 1994-04-29 2002-08-15 Univ Duke Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
AU6111896A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Test of hiv-specific t lymphocyte function that detects expo sure to hiv antigens and possibly early hiv infection
AU7465696A (en) 1995-10-20 1997-05-07 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US6592872B1 (en) 1996-09-17 2003-07-15 The United States Of America As Represented By The Department Of Health And Human Services Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
EP2286831A1 (fr) * 1997-07-10 2011-02-23 Mannkind Corporation Méthode pour induire une réponse de CTL
FR2771640B1 (fr) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
WO1999049893A1 (fr) * 1998-03-31 1999-10-07 Trustees Of Boston University Conception de conjugues moleculaires et compositions utilisant de tels conjugues
CA2350911A1 (fr) 1998-11-16 2000-05-25 Board Of Regents, The University Of Texas System Induction de lymphocytes t specifiques du vih
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
AU782193B2 (en) 1999-12-17 2005-07-07 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
WO2001054719A2 (fr) 2000-01-31 2001-08-02 Smithkline Beecham Biologicals S.A. Nouvelle utilisation
EP1307130A4 (fr) * 2000-02-04 2005-01-12 Beth Israel Hospital Vaccin contre le virus de l'immunodeficience humaine
FR2812087B1 (fr) 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
NO314588B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
EP1331942A4 (fr) 2000-09-22 2005-03-16 Univ Duke Immunogene contenant la proteine d'enveloppe du vih liee a un ligand
EP1490396A4 (fr) 2001-03-01 2006-04-19 Us Gov Health & Human Serv Peptides hiv immunogenes utilises en tant que reactifs et en tant que vaccins
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
US7153509B2 (en) 2001-11-07 2006-12-26 Duke University Immunogenic peptides comprising a T-helper epitope and a B-cell neutralizing antibody epitope
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
WO2003046137A2 (fr) 2001-11-27 2003-06-05 Duke University Immunogene du site de liaison v3-ccr5 de l'enveloppe du vih
MXPA05000874A (es) 2002-07-23 2005-03-23 Univ Duke Proteina de fusion igg fc/vih-hp 120/c3d.
CA2526339A1 (fr) 2003-05-19 2005-02-24 Duke University Immunogene polyvalent
CA2539325C (fr) 2003-09-17 2016-03-22 Duke University Immunogenes consensus/ancestraux

Also Published As

Publication number Publication date
US7078039B2 (en) 2006-07-18
CN1635876A (zh) 2005-07-06
US7052699B2 (en) 2006-05-30
WO2001056355A2 (fr) 2001-08-09
US20050112136A1 (en) 2005-05-26
BR0108210A (pt) 2002-10-22
US20010036461A1 (en) 2001-11-01
AU3328001A (en) 2001-08-14
CA2398816A1 (fr) 2001-08-09
EP1307130A1 (fr) 2003-05-07
KR20020075789A (ko) 2002-10-05
US6982086B2 (en) 2006-01-03
US20040197344A1 (en) 2004-10-07
MXPA02007478A (es) 2004-08-23
KR20070057273A (ko) 2007-06-04
JP2004503205A (ja) 2004-02-05
AU785143B2 (en) 2006-10-05
US20060008467A1 (en) 2006-01-12
EP1307130A4 (fr) 2005-01-12

Similar Documents

Publication Publication Date Title
IL150961A0 (en) Human immunodeficiency virus vaccine
HUP0301308A3 (en) Human papilloma virus treatment
GB0020953D0 (en) Vaccine
HUP0301043A3 (en) Vaccine
IL155072A0 (en) Vaccine
SI1150712T1 (sl) Pripravek cepiva proti humanem papiloma virusu
IL158107A0 (en) Human papillomaviruses vaccine
GB0130215D0 (en) Vaccine
AU1591402A (en) Vaccine
GB0024200D0 (en) Component vaccine
HUP0303372A3 (en) Vaccine
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
GB0121171D0 (en) Vaccine
GB0014288D0 (en) Vaccine
HUP0202770A3 (en) Human papilloma virus vaccine
GB0014845D0 (en) Vaccine
GB0026334D0 (en) Vaccine
GB0105606D0 (en) Immunogens and vaccines and their preparation and use
GB0025694D0 (en) Vaccine
GB0003082D0 (en) Vaccine
GB0006693D0 (en) Vaccine
GB0015722D0 (en) Vaccine
GB0027433D0 (en) Vaccine component
GB0015935D0 (en) Vaccine
GB9917981D0 (en) Viral vaccine